Epilepsy and cannabinoids: current consensus, controversies and future outlook

Today, 26 March, marks Purple Day; an international grassroots effort dedicated to increasing awareness about epilepsy across the globe. This year, we’re taking the opportunity to delve into what can be seen as a controversial area – the use of cannabis-derived therapeutics for the treatment of epilepsy. Historically, the use of such agents has been reported to improve symptoms in a number of neurological disorders, but research into the mechanisms behind this and the risks involved remains limited. However, in the past year alone, we’ve seen positive results in a number of studies investigating the use of cannabidiol, for example...